

Fifth Global Summit

September 23-25, 2021

PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Virtual Event

Scientific Program Draft- September 16, 2021

THURSDAY, SEPTEMBER 23, 2021

8:00AM

WELCOME AND INTRODUCTION

Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM

SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION

Moderators:

Jim C. Hu, MD, MPH, Ronald P. Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medical College, Cornell University; and Attending Urologist, New York-Presbyterian Hospital

Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme

Clare M. C. Tempany-Afdhal, MB BAO BCh, FACR, FISMRM, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization

8:30AM

Topic 1: State of the Art in Prostate Cancer Screening

Risk-Stratified Screening and Early Detection of Prostate Cancer in 2021: Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

8:42AM

Q & A

8:44AM

Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling

8:44AM

Topic 2A: Current and Emerging Liquid Diagnostics

8:44AM

Keynote Address - *Clinical Overview:* E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal

8:56AM

Q & A

8:58AM

Sponsored by OPKO Health - Clinical Value of 4KScore: Peter Scardino, MD, David Koch Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center; David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Visiting Professor of Urology SUNY Downstate Health Sciences University, College of Medicine; and Gregory Thoreson, MD - Urologist, Urology Clinics of North Texas

- 9:04AM** *IsoPSA®: Clinical Performance of a Single Parameter, Structure Based Test for High Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial:* Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, and Staff Member, Taussig Cancer Institute, Cleveland Clinic
- 9:10AM** Q & A
- 9:12AM** *Liquid Biopsy:* Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center, University of Toronto, Canada; and Chair, World Urologic Oncology Federation
- 9:24AM** Q & A
- 9:26AM-9:37AM** *Panel Discussion - Liquid Biomarkers:* Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University School of Medicine
- 9:37AM** *Topic 2B: The Re-Emergence of Transperineal Prostate Biopsy – Current and Future Clinical Role:* Edward Schaeffer, MD, PhD, Edmund Andrews Professor and Chair, Department of Urology, Northwestern University
- 9:49AM** Q & A
- 9:54AM** *Topic 2C: Current and Emerging Imaging Tools and Targeted Biopsies*
- 9:54AM** **Advanced Ultrasound**
- 9:54AM** *Real-Time High-Resolution Micro-Ultrasound*
- 9:54AM** *Radiologic Perspective:* Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada
- 10:06AM** *Urologic Perspective:* Rafael Sanchez-Salas, MD, Associate Professor, Department of Surgery, Division of Urology, McGill University, Canada
- 10:12AM** Q & A
- 10:14AM** *Contrast-Enhanced Ultrasound:* Ethan Halpern, MD, Professor and Vice Chair for Research; Co-Director, Prostate Diagnostic Center; and Director, Cardiac CT, Thomas Jefferson University
- 10:26AM** Q & A
- 10:29AM-11:00AM** **COFFEE BREAK**
- 11:00AM** **Multi-Parametric (mp) and Bi-Parametric (bp) Magnetic Resonance Imaging**
- 11:00AM** *Recent Advancements in PI-RADS - Risk Assessment with mpMRI vs bpMRI:* Jelle Barentsz, MD, PhD, Chair and Professor of Radiology, Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands; and Founding Member and Past-President of the International Cancer Imaging Society, and Past-President of the European Society of Urogenital Radiology
- 11:12AM** Q & A
- 11:14AM** *American College of Radiology Prostate MRI Image Quality Initiative:* Jeffrey Weinreb, MD, Professor, Department of Diagnostic Radiology and Biomedical Imaging, Yale School of Medicine and Chief of MRI Services, Yale-New Haven Hospital
- 11:24AM** Q & A
- 11:26AM** *Prostate Imaging Elevated by Deep Learning:* Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School; and Ersin Bayram, PhD, Director, Body and Oncology MRI, GE Healthcare
- 11:44AM** Q & A

- 11:46AM** ***MRI-targeted Biopsy of the Prostate***
- 11:46AM** *Optimizing Patient Selection and Technique:* Fergus Coakley, MD, Professor and Chair of Radiology, School of Medicine, Oregon Health and Science University
- 11:58PM** Q & A
- 12:01PM** *Transperineal Biopsy & Classification of Risk Using Novel Gleason Pattern Quantification:* Behfar Ehdai, MD, MPH, Urologic Surgeon, Memorial Sloan Kettering Cancer Center
- 12:07PM-12:17PM** *Panel Discussion: Imaging Modalities and Targeted Biopsies*
- 12:17PM** ***Topic 3: NCCN Guidelines for Early Detection of Prostate Cancer 2021:*** Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
- 12:23PM** Q & A
- 12:25PM** ***Topic 4: Integrated Multi-Modality Diagnostic Evaluation:*** Robert E. Reiter, MD, MBA, Bing Professor in Prostate Cancer; Director, Prostate Cancer Program and Chief, Division of Urologic Oncology; Assistant Dean, Bioentrepreneurship; Department of Urology, David Geffen School of Medicine at UCLA Institute of Urologic Oncology
- 12:37PM** Q & A
- 12:40PM-2:30PM** **LUNCH BREAK**
- 2:30PM** **SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**
- Moderators:**
- Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
- Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada
- Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine; Interim Deputy Director, Sylvester Comprehensive Care Center; and Service Chief, Radiation Oncology, Jackson Memorial Hospital
- Laurence Klotz, MD
- 2:45PM** ***Topic 1: Liquid Markers***
- 2:45PM** ***Germline Genome and Prostate Cancer Evolution and Aggressivity:*** Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
- 2:57PM** Q & A
- 2:59PM** ***Topic 2: Tissue-Based Genetic Cancer Profiling***
- 2:59PM** *Overview:* Alan Pollack, MD, PhD
- 3:12PM** Q & A
- 3:14PM** ***Topic 3: Biopsy***
- 3:14PM** ***Public Health Perspective on Targeted MRI Biopsy and Overtreatment:*** Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
- 3:25PM** Q & A
- 3:29PM-3:59PM** **COFFEE BREAK**

- 3:59PM** *Topic 4: Pathology Overview:* Thomas Wheeler, MD, Chief of Pathology and Laboratory Medicine, Baylor St. Luke's Medical Center, and W. L. Moody, Jr. Endowed Chair, Professor and Senior Vice Chair, Department of Pathology & Immunology, Baylor College of Medicine
- 4:11PM** Q & A
- 4:14PM-4:25PM** *Panel Discussion: Liquid Markers and Tissue Sampling and Analysis*
- 4:25PM** *Topic 5: In Vivo Imaging and Digital Health*
- 4:25PM** *Topic 5A: Prostate Imaging Overview:* Clare Tempany, MD
- 4:37PM** Q & A
- 4:40PM** *Experience with ¹⁸F-rhPSMA7.3:* Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany
- 4:46PM** Q & A
- 4:48PM** *Topic 5B: Doctor Knows Best? Why Prostate Cancer Care Must be Transformed into Digital Health:* Michael Johnson, MD, Director, Advanced Cancer Care Center, Oregon Institute of Urology
- 5:08PM-5:20PM** *Panel Discussion: Prostate Imaging and Digital Health*
- 5:20PM-6:00PM** **GENERAL DISCUSSION**

FRIDAY, SEPTEMBER 24, 2021

- 8:00AM** **SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)**
- Moderators:**
- Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging Co-Director, PET-MRI Research Program Stanford University
- Adam Kibel, MD. Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women's Hospital and Dana-Farber Cancer Institute
- Kelvin A. Moses, MD, PhD, FACS, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
- Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute
- 8:00AM** *Topic 5C: Molecular and Multi-Modality Imaging*
- 8:00AM** *Nuclear Medicine Overview:*
- Imaging Perspective* - Andrei H. Iagaru, MD, FACNM
- Urologic Perspective* – Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine
- 8:12AM** Q & A
- 8:14AM** *PSMA Imaging - Emerging Clinical Applications from Radiologic Perspective:* Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiologic Science, Johns Hopkins University School of Medicine
- 8:25AM** Q & A

- 8:27AM** *PSMA PET/CT Imaging - Emerging Clinical Applications from Urologic Perspective:* Neal Shore, MD, FACS, Director, CPI, Carolina Urologic Research Center; Chief Surgical Officer and Head of Urology Research, Genesis Care, US; Founding Director, CUSP: Clinical Research Consortium, Myrtle Beach, SC
- 9:03AM** Q & A
- 9:07AM** *Clinical Utility of Axumin:* Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center; and Member, National Comprehensive Cancer Network (NCCN)'s Cancer Early Detection Panel
- 9:19AM** Q & A
- 9:21AM** *Neuroendocrine Tumors Imaging and Radionuclide Treatment:* Thomas Hope, MD, Associate Professor of Radiology and Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging; Chair of the Cancer Center's Molecular Imaging & Radionuclide Therapy Site Committee, University of California, San Francisco; Chief of Nuclear Medicine at the San Francisco VA Medical Center
- 9:33AM** Q & A
- 9:36AM** *Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics:* Mohammad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center; and Participant, US Vice President Joseph Biden's Cancer Moonshot Program
- 9:47AM** Q & A
- 9:49AM-10:00AM** *Panel Discussion: Imaging Modalities and Radiogenomics*
- 10:00AM – 10:20AM** **COFFEE BREAK**
- 10:20AM** ***Topic 6: Integration of Precision Diagnosis and Precision Treatment***
- 10:20AM** *Topic 6A: Integrated Diagnostics (Radiogenomics) and Patient Selection for Active Surveillance vs. Immediate Treatment:* Sanoj Punnen, MD, MAS, Co-Chair of Genitourinary Site Disease Group, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research and Associate Professor, Department of Urology, University of Miami, Miller School of Medicine
- 10:32AM** Q & A
- 10:34AM** *Topic 6B: Selection and Monitoring of Image-Targeted Minimally Invasive Treatment:* Fiona Fennessy, MB, Bch, PhD, Associate Professor of Radiology, Harvard Medical School; Faculty Radiologist, Brigham & Women's Hospital; Program Director, Cancer Imaging Fellowship Program; and Institute Physician, Dana-Farber Cancer Institute
- 10:45AM** Q & A
- 10:47AM** *Topic 6C: Role of Imaging for Precision Radiation Treatment*
- 10:47AM** *Overview:* Ashesh Jani, MD, MSEE, FASTRO, Professor, Department of Radiation Oncology, Emory University
- 11:58AM** Q & A
- 11:00AM** *Topic 6D: Surgical Treatment*
- 11:00AM** *Overview:* Adam Feldman, MD, MPH, Urologist, Massachusetts General Hospital; Assistant Professor of Surgery, Harvard Medical School; and Director, Combined Harvard Urologic Oncology Fellowship
- 11:12AM** Q & A
- 11:14AM** *Topic 6E: NCCN Guidelines for Treatment of Localized Prostate Cancer:* Kelvin A. Moses, MD, PhD
- 11:26AM** Q & A

11:34PM-
1:19PM

LUNCH BREAK

1:19 PM

SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER

Moderators:

Neil H. Bander, MD, Bernard & Josephine Chaus Professor of Urologic Oncology, Weill Cornell Medicine

David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program

Daniel Petrylak, MD, Professor of Medicine, Director of Genitourinary Oncology and Co-Director of Signal Transduction Program, Yale University

1:34PM

Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease

1:34PM

Topic 1A: Standard Treatment and Global Prostate Cancer Issues: Mark Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA

1:43PM

Q & A

1:45PM

Topic 1B: Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape: Paul Sieber, MD, President, Medical Director, Research, Lancaster Urology

2:30PM

Topic 1C: Precision Oncology of Prostate Cancer: Daniel Petrylak, MD

2:42PM

Q & A

2:44PM

Topic 1D: Bispecific T-Cell Engager (BiTE®) Platform for Immuno-Oncology: Michael Groaning, PhD, Global Medical Affairs Lead - Prostate Cancer, Amgen

2:56PM

Topic 1E: Epigenetic Modulations and Lineage Plasticity: Himisha Beltran, MD, Associate Professor of Medicine, Harvard Medical School and Director of Translational Research, Department of Medical Oncology, Dana-Farber Cancer Institute

3:08PM

Q & A

3:11PM

Topic 1F: Novel Treatment and Its Integration with Precision Diagnostics: David Nanus, MD

3:23PM

Q & A

3:25PM –
3:40PM

Panel Discussion: Standard and Emerging Treatment

3:40PM –
4:00PM

COFFEE BREAK

4:00PM

Topic 2: Molecular and Multi-Modality Imaging and Theranostics

4:00 PM

Topic 2A: Overview: Wolfgang Weber, MD

4:12PM

Q & A

4:14PM

Topic 2B: Practical Applications and Clinical Utility of the FDA-Approved PSMA PET Imaging Agent: Implications for Urology and Radiation Oncology: Philip Koo, MD, Division Chief, Diagnostic Imaging, Banner MD Anderson Cancer Center

4:31PM

Q & A

- 4:33PM** *Topic 2C: Defining Non-Metastatic and Oligometastatic Prostate Cancer vs. Systemic Disease:* Jeremie Calais, MD, MSc, Assistant Professor, Clinical Research Program Director, Nuclear Medicine and Theranostics, University of California, Los Angeles
- 4:43PM** Q & A
- 4:45PM** *Topic 2D: Current State of the Art and Future Vision in Theranostics:* Philip Koo, MD
- 4:57PM** Q & A
- 5:00PM–5:10PM** *Panel Discussion: Molecular and Multi-Modality Imaging and Theranostics*
- 5:10PM–6:00PM** *General Discussion*
-
- 8:00AM** **SATURDAY, SEPTEMBER 25, 2021**
- SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: *Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes***
- Moderators:**
- David Albala, MD
- Scott Eggener, MD, Bruce and Beth White Family Professor of Surgery and Radiology, Vice Chair, Section of Urology and Director, High Risk and Advanced Prostate Cancer Clinic, University of Chicago
- Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
- Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine
- Stephen Zappala, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
- 8:15AM** *Overview:* Jurgen Fütterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen, and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
- 8:26AM** Q & A
- 8:28AM** *Current and Emerging Role of Radiogenomics in Risk Assessment:* John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
- 8:40AM** Q & A
- 8:42AM** *Image-Guided Laser Ablation - Experience at the University of Chicago:* Aytekin Oto, MD, Professor and Chairman of Radiology, University of Chicago
- 8:51AM** Q & A
- 8:53AM** *Follow-Up of Focal Cryoablation and Novel Pulse Sequences to Characterize the Treatment Zone:* Daniel Margolis, MD, Associate Professor of Radiology and Director, Prostate MRI and Abdominal Imaging, Weill Cornell Medicine
- 9:05AM** Q & A

- 9:07AM** *Image-Guided High Intensity Focal Ultrasound - Recent Clinical Trials:* Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
- 9:18AM** Q & A
- 9:20AM** *Whole Gland Transurethral Ultrasound Ablation – An Incision-Free Intervention with Real-Time Vision Performed Within the MR Suite:* Robert Princenthal, MD, Medical Director, Prostate Imaging and Interventions, RadNet; President, Rolling Oaks Radiology
- 9:26AM** Q & A
- 9:30AM-10:00AM** **COFFEE BREAK**
- 10:00AM** *Urologic Perspective on Clinical Utility and Outcomes:* Jim Hu, MD, MPH
- 10:12AM** Q & A
- 10:14AM** *Radiation Oncology Perspective:* Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
- 10:26AM** Q & A
- 10:30AM** *Emerging Data on the Current and Future Role of Image-Guided Treatment in Prostate Cancer Care:* Scott Eggener, MD
- 10:42AM** Q & A
- 10:44AM-11:00AM** *Panel Discussion: Image-Guided Treatment*
- 11:00AM-1:00PM** **LUNCH BREAK**
- 1:00PM** **PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER**
- Moderators:**
- Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
- Quoc-Dien Trinh, MD, Co-Director, Dana-Farber/Brigham and Women's Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
- 1:00PM** *Overview of Emerging Data:* Quoc-Dien Trinh, MD
- 1:12PM** Q & A
- 1:17PM** *Current State of Knowledge - Genetics and Health Disparities:* Adam B Murphy, MD, MBA, MSCI
- 1:29PM** Q & A
- 1:30PM-1:45PM** *Panel Discussion: Health Disparities*

1:45PM **PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT**

Moderators:

Paul Boutros, PhD, MBA and Masoom Haider

Arnold C Cinman, MD, FACS, Partner, Tower Urology; and Attending Urologist, Cedars-Sinai Medical Center, Los Angeles

Rakesh Shiradkar, PhD, Research Assistant Professor, Biomedical Engineering, Case Western Reserve University, Member, Case Comprehensive Cancer Center

1:45PM *Personalization of Prostate Cancer Care through Integration of Data:* Ilya Gipp, MD, PhD, Oncology Solutions Subject Matter Expert, Philips

2:16PM Q & A

2:18PM *Clinical Perspective on the Emerging and Potential Role of Machine Learning:* Masoom Haider, MD

2:28PM Q & A

2:30PM *Radiomics and Pathomics of Prostate Cancer: Diagnosis, Prognosis and Predicting Treatment Response:* Anant Madabhushi, PhD, FAIMBE, FIEEE, FNAI, Donnell Institute Professor and Director, Center for Computational Imaging & Personalized Diagnostics, Departments of Biomedical Engineering, Urology, Radiology, Pathology, Radiation Oncology, Electrical, Comp & Systems Engineering, Computer & Data Sciences and Gen Med Sciences, Case Western Reserve University

2:42PM Q & A

2:44PM *Artificial Intelligence:* Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China

2:56PM Q & A

2:59PM *Update on Multi-Factorial Nomograms:* Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center & Andreas G. Wibmer, MD, Assistant Attending, Department of Radiology, Memorial Sloan Kettering Cancer Center

3:05PM Q & A

3:07PM-3:30PM *Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning*

3:30PM-3:50PM **Presentation of Winning Abstracts:**

Place #1: Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial): Scott Eggener, MD

Place #2 (tied): Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer; Analysis from Two Prospective Clinical Trials: Gerald L. Andriole, MD

Place #2 (tied): IsoPSA®: Clinical Performance of a Single Parameter, Structure-Based Test for High-Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial: Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc.

Place #3: OSPREY and CONDOR: Results from Two Registrational Clinical Studies Assessing the Diagnostic Performance of Piflufolastat F 18 (PYLARIFY®) PET/CT in Patients with High-Risk and Recurrent Prostate Cancer: Bela Denes, MD, Vice President Global Medical Affairs, Lantheus Medical Imaging

3:50PM-5:30PM **SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS**

5:30PM **ADJOURN**